10x Genomics, Inc. 8-K

What Happened
10x Genomics, Inc. announced the results of its annual meeting held June 4, 2026 (filed on Form 8-K June 8, 2026). Holders of 117,542,161 shares (representing 198,815,518 votes, or ~90.5% of 219,700,782 eligible votes) participated virtually or by proxy, establishing a quorum. Stockholders elected three Class I directors—Serge Saxonov, Benjamin J. Hindson and John R. Stuelpnagel—for three‑year terms, ratified Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal 2026, and approved the non‑binding advisory vote on executive compensation (say‑on‑pay).

Key Details

• Meeting date and filing: Annual Meeting June 4, 2026; Form 8‑K filed June 8, 2026.
• Director election vote totals:
  • Serge Saxonov — For: 164,137,381; Against: 15,559,860; Abstain: 557,329; Broker non‑votes: 18,560,948.
  • Benjamin J. Hindson — For: 162,942,766; Against: 16,761,532; Abstain: 550,270; Broker non‑votes: 18,560,950.
  • John R. Stuelpnagel — For: 155,628,365; Against: 24,072,179; Abstain: 554,023; Broker non‑votes: 18,560,951.
• Auditor ratification: Ernst & Young LLP ratified — For: 197,719,939; Against: 458,231; Abstain: 637,346 (no broker non‑votes).
• Say‑on‑pay (advisory) approved — For: 176,677,540; Against: 2,828,730; Abstain: 748,296; Broker non‑votes: 18,560,952.

Why It Matters
Board elections and auditor ratification shape corporate governance and oversight. The re‑election of the three Class I directors maintains board continuity; ratifying Ernst & Young avoids a change in the company’s auditor for fiscal 2026. The strong advisory vote in favor of executive compensation indicates shareholder support for the company’s pay practices (though advisory and non‑binding). High participation (~90.5% of eligible votes) reflects substantial shareholder engagement in these governance matters.